A Phase 2 interventional study of GSK2140944 Lyophile and GSK2140944 Capsules in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-17.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.
Among the 11 studies testing gepotidacin in Bacterial Infections, this one has the largest enrollment, is one of 2 that started in 2014, is one of 2 in phase 2, and was the 2nd registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2014.
This study's enrollment of 126 is above the median of 84 across 382 interventional studies indexed under Bacterial Infections.
Median enrollment 34 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Bacterial Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2014, is one of 4 in phase 2, and was the 21st registered.
GlaxoSmithKline’s Bacterial Infections studies by the year they started, since 2005.
1 of the studies testing gepotidacin in Bacterial Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing gepotidacin in Bacterial Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Bacterial Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
GSK2140944 belongs to a novel structural class of antibiotics - Bacterial Type II Topoisomerase Inhibitors (BTI). This is a Phase II, randomized, two-part, multicenter study designed to select the optimal dose by further characterizing the safety, tolerability and PK of GSK 2140944 and by evaluating efficacy in subjects requiring in-patient medical care to treat their suspected or confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSI). The selected dose will be used in future studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: All subjects will be screened for Hepatitis B surface antigen and Hepatitis C ribonucleic acid (RNA), but these results will not be used to determine subject eligibility or subject continuation in the study after enrollment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily \[BID\]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
Drug: GSK2140944 Lyophile · Drug: GSK2140944 Capsules
Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
Drug: GSK2140944 Lyophile · Drug: GSK2140944 Capsules
Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
Drug: GSK2140944 Lyophile · Drug: GSK2140944 Capsules
GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate
Cure rate and withdrawal rate data points was jointly assessed in a composite endpoint for all participants who received at least one dose of GSK2140944. Cure rate was defined as the percentage of participants exhibiting clinical improvement (=\>20% reduction in overall lesion area) at the early efficacy visit. Withdrawal rate was defined as the percentage of participants who withdrew from study treatment due to a drug-related adverse event (AE) at any point while on treatment.
Time frame: Up to Day 3
Number of Participants With Clinical Response and Outcome at Early Efficacy Visit
The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.
Time frame: Up to Day 3
Number of Participants With Clinical Response and Outcome at the Post Therapy Visit (Day 12-18)
The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.
Time frame: Day 12 to Day 18
Number of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28)
The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as no increase in the total surface area of the lesion (as calculated by digital imaging) compared to post therapy visit and no further administration of antibacterial therapy for the lesion under study. Clinical recurrence was defined as death of participant; increase in the area of the lesion compared to post therapy visit or administration of additional antibacterial therapy for the lesion under study before the efficacy endpoint assessment for participants who were a clinical success at post therapy visit. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.
Time frame: Day 21 to Day 28
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA in lesion sample has been presented.
Time frame: Up to Day 3
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MRSA in lesion sample has been presented.
Time frame: Day 3
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-susceptible Staphylococcus Aureus (MSSA) in Lesion Sample
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MSSA in lesion sample has been presented.
Time frame: Up to Day 3
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for other Gram-positive aerobic pathogens in lesion sample has been presented.
Time frame: Up to Day 3
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for all Gram-positive aerobic pathogens in lesion sample has been presented.
Time frame: Up to Day 3
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample
The microbiological outcome was determined by comparing Baseline bacteriology blood culture, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA, MRSA and all Gram-positive aerobic pathogens in blood sample has been presented.
Time frame: Up to Day 3
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained at post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA in lesion sample has been presented.
Time frame: Day 12 to Day 18
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA in lesion sample has been presented.
Time frame: Day 12 to Day 18
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA in lesion sample has been presented.
Time frame: Day 12 to Day 18
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.
Time frame: Day 12 to Day 18
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.
Time frame: Day 12 to Day 18
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.
Time frame: Day 12 to Day 18
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA pathogen in lesion sample has been presented.
Time frame: Day 21 to Day 28
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA pathogen in lesion sample has been presented.
Time frame: Day 21 to Day 28
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MSSA in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA pathogen in lesion sample has been presented.
Time frame: Day 21 to Day 28
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for other Gram-positive aerobic pathogens in lesion sample has been presented.
Time frame: Day 21 to Day 28
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for all Gram-positive aerobic pathogens in lesion sample has been presented.
Time frame: Day 21 to Day 28
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample
Microbiological outcome was determined by comparing Baseline blood culture, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA, MRSA and all Gram-positive aerobic pathogens in lesion sample has been presented.
Time frame: Day 21 to Day 28
Pharmacokinetic (PK) Parameters (From GSK2140944 Plasma Concentration-time Data): Maximum Observed Concentration (Cmax) on IV Therapy
Samples for assessment of PK parameter Cmax was done on at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.
Time frame: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Cmax on Oral Dose Therapy
Samples for assessment of PK parameter Cmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.
Time frame: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Time to Cmax (Tmax) on IV Therapy
Samples for assessment of PK parameter tmax was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.
Time frame: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Tmax on Oral Dose Therapy
Samples for assessment of PK parameter tmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.
Time frame: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Time of the Last Quantifiable Concentration [AUC (0-t)] and AUC Over the Dosing Interval [AUC(0-tau)] on IV Therapy
Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on IV therapy has been presented.
Time frame: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3
PK Parameters (From GSK2140944 Plasma Concentration-time Data): AUC (0-t) and AUC(0-tau) on Oral Dose Therapy
Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on oral dose therapy has been presented.
Time frame: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)
Number of Participants Demonstrating a Decrease in GSK2140944 Susceptibility When Comparing Isolates Recovered From Baseline With Those From Any Time Post-Baseline Skin Specimens
Reduction in susceptibility was defined as a \>=4-fold increase in minimum inhibitory concentration (MIC) or \>=6 millimeter decrease in zone size between an isolate obtained at Baseline and the same pathogen at subsequent visits.
Time frame: Up to Day 28
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or all events of possible drug-induced liver injury with hyperbilirubinemia.
Time frame: Up to Day 28
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Pulse Rate
Pulse rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Respiratory Rate
Respiratory rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Vital Sign: Body Temperature
Body temperature was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings
The 12-lead ECGs was obtained at Day 1, Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for corrected QT, using Fridericia formula (QTcF), corrected QT using Bazett's formula (QTcB) and QRS intervals. The number of participants with maximum post-baseline ECG value exceeding the following limits have been reported: QTcB/QTcF interval \> 450 and ≤ 480 millisecond (msec), QTcB/QTcF interval \> 480 and ≤ 500 msec, QTcB/QTcF interval \> 500 msec, QRS interval \< 70 msec and QRS interval \> 120 msec.
Time frame: Up to Day 28
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT)
Blood samples for assessment of clinical chemistry parameters of ALT, ALP, AST, FSH and GGT was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate
Blood samples for assessment of clinical chemistry parameters of bilirubin, creatinine, direct bilirubin and urate was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Clinical Chemistry Parameters: Calcium, Carbon Dioxide, Chloride, Glucose, Magnesium, Potassium, Sodium and Urea
Blood samples for assessment of clinical chemistry parameters of calcium, carbon dioxide, chloride, glucose, magnesium, potassium, sodium and urea was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated
Blood samples for assessment of clinical chemistry parameter of estimated creatinine clearance was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Estradiol Values at Baseline
Blood samples for assessment of clinical chemistry parameter of estradiol was collected at Baseline (Day 1). No post-baseline values were reported.
Time frame: Baseline (Day 1)
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples for assessment of hematology parameters of basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin Concentration (EMCHC) and Hemoglobin
Blood samples for assessment of hematology parameters of EMCHC and hemoglobin was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin (EMCH)
Blood samples for assessment of hematology parameter of EMCH was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Volume (EMCV)
Blood samples for assessment of hematology parameter of EMCV was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Hematology Parameters: Erythrocytes
Blood samples for assessment of hematology parameter of erythrocyte was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Change From Baseline in Hematology Parameters: Hematocrit
Blood samples for assessment of hematology parameter of hematocrit was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
Time frame: Baseline (Day 1) up to Day 28
Number of Participants With Abnormal Urinalysis Dipstick Results
Samples for urinalysis assessment was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for Glucose, Ketones, Occult Blood, Protein and pH. Participants with abnormal urinalysis result was reported.
Time frame: Up to day 28
This study was conducted at 13 centers in the United States from 24 March 2014 to 22 July 2015.
| Milestone | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Started | 58 | 39 | 25 |
| Completed | 51 | 32 | 24 |
| Not completed | 7 | 7 | 1 |
| Withdrew: Adverse event | 3 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 |
Cure rate and withdrawal rate data points was jointly assessed in a composite endpoint for all participants who received at least one dose of GSK2140944. Cure rate was defined as the percentage of participants exhibiting clinical improvement (=\>20% reduction in overall lesion area) at the early efficacy visit. Withdrawal rate was defined as the percentage of participants who withdrew from study treatment due to a drug-related adverse event (AE) at any point while on treatment.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Number Cured | 48 | 28 | 23 |
| Number Withdrawn | 1 | 0 | 0 |
The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Clinical Success | 48 | 28 | 23 |
| Clinical Failure | 7 | 7 | 2 |
| Unable to Determine | 3 | 4 | 0 |
The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Clinical Success | 52 | 32 | 21 |
| Clinical Failure | 1 | 1 | 1 |
| Unable to Determine | 5 | 6 | 3 |
The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as no increase in the total surface area of the lesion (as calculated by digital imaging) compared to post therapy visit and no further administration of antibacterial therapy for the lesion under study. Clinical recurrence was defined as death of participant; increase in the area of the lesion compared to post therapy visit or administration of additional antibacterial therapy for the lesion under study before the efficacy endpoint assessment for participants who were a clinical success at post therapy visit. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Clinical Success | 50 | 28 | 20 |
| Clinical Failure | 1 | 1 | 1 |
| Clinical Recurrence | 2 | 1 | 1 |
| Unable to Determine | 5 | 9 | 3 |
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 0 | 2 | 0 |
| Microbiological Success, Presumed Eradication | 24 | 17 | 9 |
| Microbiological Failure, Persistence | 11 | 3 | 2 |
| Microbiological Failure, Presumed Persistence | 4 | 6 | 0 |
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MRSA in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 0 | 2 | 0 |
| Microbiological Success, Presumed Eradication | 18 | 10 | 4 |
| Microbiological Failure, Persistence | 7 | 3 | 1 |
| Microbiological Failure, Presumed Persistence | 4 | 5 | 0 |
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MSSA in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Presumed Eradication | 6 | 7 | 5 |
| Microbiological Failure, Persistence | 4 | 0 | 1 |
| Microbiological Failure, Presumed Persistence | 0 | 1 | 0 |
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for other Gram-positive aerobic pathogens in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 2 | 2 | 0 |
| Microbiological Success, Presumed Eradication | 0 | 1 | 3 |
| Microbiological Failure, Presumed Persistence | 1 | 1 | 0 |
| Microbiological Failure, Unable to Determine | 1 | 0 | 0 |
The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for all Gram-positive aerobic pathogens in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 2 | 4 | 0 |
| Microbiological Success, Presumed Eradication | 24 | 18 | 12 |
| Microbiological Failure, Persistence | 11 | 3 | 2 |
| Microbiological Failure, Presumed Persistence | 5 | 7 | 0 |
| Microbiological Failure, Unable to Determine | 1 | 0 | 0 |
The microbiological outcome was determined by comparing Baseline bacteriology blood culture, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA, MRSA and all Gram-positive aerobic pathogens in blood sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h |
|---|---|
| SA, Microbiological Success, Eradication | 2 |
| MRSA, Microbiological Success, Eradication | 2 |
| Aerobic, Microbiological Success, Eradication | 2 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained at post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 3 | 1 | 0 |
| Microbiological Success, Presumed Eradication | 32 | 24 | 8 |
| Microbiological Failure, Presumed Persistence | 3 | 2 | 1 |
| Microbiological Failure, Presumed Recurrence | 1 | 1 | 2 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 3 | 0 | 0 |
| Microbiological Success, Presumed Eradication | 22 | 17 | 4 |
| Microbiological Failure, Presumed Persistence | 3 | 2 | 0 |
| Microbiological Failure, Presumed Recurrence | 1 | 1 | 1 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 0 | 1 | 0 |
| Microbiological Success, Presumed Eradication | 10 | 7 | 4 |
| Microbiological Failure, Presumed Persistence | 0 | 0 | 1 |
| Microbiological Failure, Presumed Recurrence | 0 | 0 | 1 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Presumed Eradication | 3 | 3 | 2 |
| Microbiological Failure, Presumed Persistence | 0 | 1 | 0 |
| Microbiological Failure, Presumed Recurrence | 1 | 0 | 1 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 3 | 1 | 0 |
| Microbiological Success, Presumed Eradication | 35 | 27 | 10 |
| Microbiological Failure, Presumed Persistence | 3 | 3 | 1 |
| Microbiological Failure, Presumed Recurrence | 2 | 1 | 3 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.
| Number of pathogens | Gepotidacin 750 mg q12h |
|---|---|
| SA, Microbiological Success, Presumed Eradication | 2 |
| MRSA, Microbiological Success,Presumed Eradication | 2 |
| Aerobic,MicrobiologicalSuccess,PresumedEradication | 2 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA pathogen in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 1 | 0 | 0 |
| Microbiological Success, Presumed Eradication | 33 | 21 | 8 |
| Microbiological Failure, Presumed Recurrence | 1 | 4 | 0 |
| Microbiological Failure, Unable to Determine | 4 | 3 | 3 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA pathogen in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 1 | 0 | 0 |
| Microbiological Success, Presumed Eradication | 23 | 14 | 4 |
| Microbiological Failure, Presumed Recurrence | 1 | 3 | 0 |
| Microbiological Failure, Unable to Determine | 4 | 3 | 1 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA pathogen in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Presumed Eradication | 10 | 7 | 4 |
| Microbiological Failure, Presumed Recurrence | 0 | 1 | 0 |
| Microbiological Failure, Unable to Determine | 0 | 0 | 2 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for other Gram-positive aerobic pathogens in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Presumed Eradication | 3 | 2 | 2 |
| Microbiological Failure, Presumed Recurrence | 0 | 1 | 0 |
| Microbiological Failure, Unable to Determine | 1 | 1 | 1 |
Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for all Gram-positive aerobic pathogens in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Microbiological Success, Eradication | 1 | 0 | 0 |
| Microbiological Success, Presumed Eradication | 36 | 23 | 10 |
| Microbiological Failure, Presumed Recurrence | 1 | 5 | 0 |
| Microbiological Failure, Unable to Determine | 5 | 4 | 4 |
Microbiological outcome was determined by comparing Baseline blood culture, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA, MRSA and all Gram-positive aerobic pathogens in lesion sample has been presented.
| Number of pathogens | Gepotidacin 750 mg q12h |
|---|---|
| SA, Microbiological Success, Presumed Eradication | 2 |
| MRSA,Microbiological Success,Presumed Eradication | 2 |
| Aerobic,MicrobiologicalSuccess,PresumedEradication | 2 |
Samples for assessment of PK parameter Cmax was done on at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.
| Nanograms per milliliter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Pharmacokinetic (PK) Parameters (From GSK2140944 Plasma Concentration-time Data): Maximum Observed Concentration (Cmax) on IV Therapy | 4590 ± 42.4 | 6059 ± 29.8 | 8848 ± 105.5 |
Samples for assessment of PK parameter Cmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.
| Nanograms per milliliter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| PK Parameters (From GSK2140944 Plasma Concentration-time Data): Cmax on Oral Dose Therapy | 2342 ± 84.7 | 4329 ± 67.8 | 3858 ± 94.1 |
Samples for assessment of PK parameter tmax was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.
| Hours | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| PK Parameters (From GSK2140944 Plasma Concentration-time Data): Time to Cmax (Tmax) on IV Therapy | 1.95 (0.00 to 3.05) | 1.90 (0.90 to 3.00) | 1.93 (0.00 to 3.00) |
Samples for assessment of PK parameter tmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.
| Hours | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| PK Parameters (From GSK2140944 Plasma Concentration-time Data): Tmax on Oral Dose Therapy | 3.00 (0.95 to 12.00) | 2.92 (1.02 to 12.00) | 2.98 (0.98 to 8.00) |
Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on IV therapy has been presented.
| Hour nanograms per milliliter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| AUClast | 15992 ± 36.7 | 20904 ± 31.8 | 20851 ± 64.8 |
| AUC0-tau | 16159 ± 36.3 | 20815 ± 31.7 | 21499 ± 66.9 |
Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on oral dose therapy has been presented.
| Hour nanograms per milliliter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| AUClast | 11965 ± 101.7 | 19308 ± 98.8 | 15923 ± 117.4 |
| AUC0-tau | 14404 ± 78.2 | 24253 ± 65.4 | 19300 ± 77.9 |
Reduction in susceptibility was defined as a \>=4-fold increase in minimum inhibitory concentration (MIC) or \>=6 millimeter decrease in zone size between an isolate obtained at Baseline and the same pathogen at subsequent visits.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Number of Participants Demonstrating a Decrease in GSK2140944 Susceptibility When Comparing Isolates Recovered From Baseline With Those From Any Time Post-Baseline Skin Specimens | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or all events of possible drug-induced liver injury with hyperbilirubinemia.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Any AEs | 41 | 25 | 18 |
| Any SAEs | 1 | 1 | 0 |
SBP and DBP was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Millimeters of mercury | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| SBP, ON IV TREATMENT/DAY 1 | -2.9 ± 15.07 | -1.7 ± 13.90 | -2.4 ± 9.43 |
| SBP, ON IV TREATMENT/DAY 2 | -4.8 ± 14.63 | 0.3 ± 13.55 | -1.9 ± 9.73 |
| SBP, ON IV TREATMENT/DAY 3 | -1.7 ± 14.57 | 1.6 ± 11.25 | -2.1 ± 13.88 |
| SBP, ON IV TREATMENT/DAY 4 | -3.2 ± 14.25 | -1.2 ± 17.11 | -22.0 ± 31.11 |
| SBP, ON IV TREATMENT/DAY 5 | -4.8 ± 17.90 | -1.6 ± 31.01 | — |
| SBP, ON IV TREATMENT/DAY 6 | -8.0 ± 14.60 | -2.7 ± 14.83 | — |
| SBP, ON IV TREATMENT/DAY 7 | -17.0 ± 16.57 | 2.3 ± 32.39 | — |
| SBP, ON IV TREATMENT/DAY 8 | -10.3 ± 29.87 | — | — |
| SBP, ON IV TREATMENT/DAY 9 | 12.0 ± 1.41 | — | — |
| SBP, ON IV TREATMENT/DAY 10 | 6.0 ± NA | — | — |
| SBP, ORAL - FIRST DAY | 1.6 ± 13.36 | 2.3 ± 13.86 | -3.7 ± 13.59 |
| SBP, ORAL - DAY 7-10 | 2.8 ± 9.14 | 1.9 ± 10.55 | -0.9 ± 17.91 |
| SBP, POST THERAPY DAY 12-18 | -0.1 ± 13.71 | 4.5 ± 11.33 | 4.1 ± 11.09 |
| SBP, FOLLOW UP DAY 21-28 | 2.5 ± 12.87 | 2.1 ± 12.24 | 1.7 ± 15.60 |
| SBP, POST DOSE DAY 3-10 | -23.0 ± NA | — | — |
| DBP, ON IV TREATMENT/DAY 1 | -3.1 ± 10.28 | -2.9 ± 10.97 | -2.3 ± 9.21 |
| DBP, ON IV TREATMENT/DAY 2 | -3.5 ± 10.84 | -0.9 ± 9.26 | -2.1 ± 9.77 |
| DBP, ON IV TREATMENT/DAY 3 | -4.5 ± 10.98 | -0.9 ± 9.93 | -3.5 ± 14.74 |
| DBP, ON IV TREATMENT/DAY 4 | -1.9 ± 12.19 | 0.6 ± 11.19 | -12.5 ± 30.41 |
| DBP, ON IV TREATMENT/DAY 5 | -0.9 ± 13.66 | -2.0 ± 14.83 | — |
| DBP, ON IV TREATMENT/DAY 6 | -1.4 ± 11.75 | -9.2 ± 15.38 | — |
| DBP, ON IV TREATMENT/DAY 7 | -1.6 ± 23.37 | -13.8 ± 19.09 | — |
| DBP, ON IV TREATMENT/DAY 8 | -0.3 ± 18.50 | — | — |
| DBP, ON IV TREATMENT/DAY 9 | 13.0 ± 21.21 | — | — |
| DBP, ON IV TREATMENT/DAY 10 | 8.0 ± NA | — | — |
| DBP, ORAL - FIRST DAY | 0.0 ± 11.26 | -1.0 ± 8.44 | -3.4 ± 12.84 |
| DBP, ORAL - DAY 7-10 | -1.2 ± 9.12 | 0.4 ± 8.13 | 0.0 ± 11.13 |
| DBP, POST THERAPY DAY 12-18 | 2.2 ± 9.18 | 2.3 ± 8.00 | 3.5 ± 12.23 |
| DBP, FOLLOW UP DAY 21-28 | 2.3 ± 11.00 | 0.0 ± 9.94 | 1.2 ± 13.44 |
| DBP, POST DOSE DAY 3-10 | -5.0 ± NA | — | — |
Pulse rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Beats per minute | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 1 | -4.5 ± 11.38 | -3.8 ± 10.66 | -2.0 ± 10.39 |
| ON IV TREATMENT/DAY 2 | -6.3 ± 14.31 | -1.2 ± 10.66 | -5.2 ± 10.78 |
| ON IV TREATMENT/DAY 3 | -7.5 ± 14.08 | -6.6 ± 10.28 | -7.1 ± 12.62 |
| ON IV TREATMENT/DAY 4 | -11.3 ± 18.27 | -5.5 ± 10.37 | -7.0 ± 12.73 |
| ON IV TREATMENT/DAY 5 | -15.1 ± 22.36 | -9.9 ± 13.50 | — |
| ON IV TREATMENT/DAY 6 | -16.9 ± 21.60 | -11.0 ± 10.22 | — |
| ON IV TREATMENT/DAY 7 | -28.4 ± 33.57 | -18.0 ± 16.75 | — |
| ON IV TREATMENT/DAY 8 | -32.3 ± 15.63 | — | — |
| ON IV TREATMENT/DAY 9 | -45.5 ± 31.82 | — | — |
| ON IV TREATMENT/DAY 10 | -68.0 ± NA | — | — |
| ORAL - FIRST DAY | -6.7 ± 15.43 | -5.6 ± 13.47 | -7.0 ± 11.45 |
| ORAL - DAY 7-10 | -1.6 ± 12.35 | -1.8 ± 10.53 | -5.7 ± 15.33 |
| POST THERAPY DAY 12-18 | -1.6 ± 15.02 | 2.7 ± 13.38 | -7.0 ± 16.34 |
| FOLLOW UP DAY 21-28 | -1.6 ± 13.59 | -1.1 ± 10.09 | -2.5 ± 17.10 |
| POST DOSE DAY 3-10 | -15.0 ± NA | — | — |
Respiratory rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Breaths per minute | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 1 | -0.4 ± 2.66 | -0.1 ± 1.64 | 0.7 ± 2.90 |
| ON IV TREATMENT/DAY 2 | 0.1 ± 2.28 | -0.3 ± 2.37 | -0.5 ± 1.73 |
| ON IV TREATMENT/DAY 3 | 0.3 ± 2.80 | -0.6 ± 1.58 | -0.3 ± 2.17 |
| ON IV TREATMENT/DAY 4 | -0.1 ± 1.78 | -1.0 ± 1.94 | -1.0 ± 1.41 |
| ON IV TREATMENT/DAY 5 | -0.4 ± 2.22 | -0.7 ± 1.25 | — |
| ON IV TREATMENT/DAY 6 | -0.1 ± 2.33 | -0.8 ± 1.47 | — |
| ON IV TREATMENT/DAY 7 | -1.2 ± 2.68 | -1.0 ± 1.15 | — |
| ON IV TREATMENT/DAY 8 | -1.3 ± 4.16 | — | — |
| ON IV TREATMENT/DAY 9 | -4.0 ± 2.83 | — | — |
| ON IV TREATMENT/DAY 10 | -6.0 ± NA | — | — |
| ORAL - FIRST DAY | 0.4 ± 2.33 | 0.3 ± 1.66 | 0.2 ± 1.92 |
| ORAL - DAY 7-10 | -0.2 ± 2.39 | -0.1 ± 2.35 | -0.2 ± 2.04 |
| POST THERAPY DAY 12-18 | 0.0 ± 2.94 | -0.3 ± 1.97 | -0.4 ± 2.02 |
| FOLLOW UP DAY 21-28 | -0.6 ± 2.81 | -0.3 ± 2.04 | -0.5 ± 1.78 |
| POST DOSE DAY 3-10 | -2.0 ± NA | — | — |
Body temperature was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Celcius | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 1 | -0.126 ± 0.6632 | -0.053 ± 0.4114 | -0.172 ± 0.4208 |
| ON IV TREATMENT/DAY 2 | -0.195 ± 0.6058 | -0.173 ± 0.4642 | -0.400 ± 0.5672 |
| ON IV TREATMENT/DAY 3 | -0.393 ± 0.5986 | -0.308 ± 0.4216 | -0.456 ± 0.7548 |
| ON IV TREATMENT/DAY 4 | -0.476 ± 0.7242 | -0.455 ± 0.5610 | -0.550 ± 0.2121 |
| ON IV TREATMENT/DAY 5 | -0.662 ± 0.8412 | -0.521 ± 0.6013 | — |
| ON IV TREATMENT/DAY 6 | -1.080 ± 0.9589 | -0.842 ± 1.0670 | — |
| ON IV TREATMENT/DAY 7 | -1.400 ± 1.1726 | -0.738 ± 0.8901 | — |
| ON IV TREATMENT/DAY 8 | -0.533 ± 0.6110 | — | — |
| ON IV TREATMENT/DAY 9 | -0.800 ± 0.7071 | — | — |
| ON IV TREATMENT/DAY 10 | -1.100 ± NA | — | — |
| ORAL - FIRST DAY | -0.398 ± 0.8149 | -0.304 ± 0.7005 | -0.608 ± 0.7593 |
| ORAL - DAY 7-10 | -0.498 ± 0.6496 | -0.468 ± 0.6417 | -0.635 ± 0.8483 |
| POST THERAPY DAY 12-18 | -0.485 ± 0.7579 | -0.439 ± 0.6764 | -0.645 ± 0.9379 |
| FOLLOW UP DAY 21-28 | -0.441 ± 0.7579 | -0.375 ± 0.7255 | -0.604 ± 0.8891 |
| POST DOSE DAY 3-10 | -0.200 ± NA | — | — |
The 12-lead ECGs was obtained at Day 1, Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for corrected QT, using Fridericia formula (QTcF), corrected QT using Bazett's formula (QTcB) and QRS intervals. The number of participants with maximum post-baseline ECG value exceeding the following limits have been reported: QTcB/QTcF interval \> 450 and ≤ 480 millisecond (msec), QTcB/QTcF interval \> 480 and ≤ 500 msec, QTcB/QTcF interval \> 500 msec, QRS interval \< 70 msec and QRS interval \> 120 msec.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| QTcB, Maximum Post-Baseline, <=450 | 27 | 15 | 9 |
| QTcB, Maximum Post-Baseline, <=450 and <=480 | 28 | 19 | 11 |
| QTcB, Maximum Post-Baseline, >480 and <=500 | 3 | 4 | 3 |
| QTcB, Maximum Post-Baseline, >500 | 0 | 0 | 2 |
| QTcF, Maximum Post-Baseline, <=450 | 47 | 28 | 17 |
| QTcF, Maximum Post-Baseline, <=450 and <=480 | 11 | 10 | 8 |
| QRS, Maximum Post-Baseline, 70 - 120 | 56 | 36 | 23 |
| QRS, Maximum Post-Baseline, >120 | 2 | 2 | 2 |
Blood samples for assessment of clinical chemistry parameters of ALT, ALP, AST, FSH and GGT was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| International units per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ALT, ON IV TREATMENT/DAY 2 | -1.9 ± 5.40 | -1.0 ± 4.67 | 2.3 ± 14.57 |
| ALT, ON IV TREATMENT/DAY 3 | 1.2 ± 14.63 | 1.4 ± 9.71 | 1.2 ± 6.30 |
| ALT, ON IV TREATMENT/DAY 4 | — | 14.0 ± NA | — |
| ALT, ON IV TREATMENT/DAY 5 | 9.3 ± 18.27 | 2.8 ± 9.89 | — |
| ALT, ON IV TREATMENT/DAY 7 | 37.5 ± 19.09 | 18.5 ± 9.19 | — |
| ALT, ORAL - FIRST DAY | 3.6 ± 17.52 | 4.1 ± 11.58 | 5.7 ± 11.57 |
| ALT, ORAL - DAY 7-10 | 6.6 ± 15.75 | 7.3 ± 17.74 | 6.3 ± 12.60 |
| ALT, POST THERAPY DAY 12-18 | 12.8 ± 35.54 | 8.3 ± 21.90 | 4.2 ± 16.02 |
| ALT, FOLLOW UP DAY 21-28 | 36.2 ± 53.78 | 27.8 ± 39.03 | 9.3 ± 4.62 |
| ALT, POST DOSE DAY 3-10 | 22.0 ± NA | — | — |
| ALP, ON IV TREATMENT/DAY 2 | -1.4 ± 11.52 | -1.3 ± 12.27 | -4.0 ± 12.23 |
| ALP, ON IV TREATMENT/DAY 3 | 1.8 ± 18.97 | 5.7 ± 14.17 | -0.4 ± 6.17 |
| ALP, ON IV TREATMENT/DAY 4 | — | 15.0 ± NA | — |
| ALP, ON IV TREATMENT/DAY 5 | -0.3 ± 13.01 | 5.0 ± 11.49 | — |
| ALP, ON IV TREATMENT/DAY 7 | 3.0 ± 22.63 | 10.0 ± 21.21 | — |
| ALP, ORAL - FIRST DAY | 5.1 ± 19.30 | 4.0 ± 17.38 | -0.4 ± 11.32 |
| ALP, ORAL - DAY 7-10 | 3.8 ± 13.21 | 2.2 ± 19.16 | -0.1 ± 11.17 |
| ALP, POST THERAPY DAY 12-18 | -0.8 ± 15.97 | 0.1 ± 16.16 | -1.8 ± 11.72 |
| ALP, FOLLOW UP DAY 21-28 | 4.6 ± 19.49 | 15.6 ± 20.84 | -2.0 ± 3.61 |
| ALP, POST DOSE DAY 3-10 | 17.0 ± NA | — | — |
| AST, ON IV TREATMENT/DAY 2 | -1.1 ± 6.58 | 0.7 ± 7.03 | 2.0 ± 10.85 |
| AST, ON IV TREATMENT/DAY 3 | 1.6 ± 12.47 | 6.2 ± 22.30 | 6.9 ± 18.84 |
| AST, ON IV TREATMENT/DAY 4 | — | 22.0 ± NA | — |
| AST, ON IV TREATMENT/DAY 5 | 7.4 ± 17.95 | 4.2 ± 13.01 | — |
| AST, ON IV TREATMENT/DAY 7 | 23.0 ± NA | 22.0 ± 0.00 | — |
| AST, ORAL - FIRST DAY | 4.3 ± 13.34 | 34 ± 13.52 | 6.3 ± 17.83 |
| AST, ORAL - DAY 7-10 | 6.7 ± 12.08 | 6.8 ± 13.93 | 2.3 ± 17.44 |
| AST, POST THERAPY DAY 12-18 | 10.9 ± 18.98 | 9.0 ± 15.53 | 0.8 ± 19.05 |
| AST, FOLLOW UP DAY 21-28 | 16.2 ± 22.15 | 22.6 ± 29.90 | 5.3 ± 2.52 |
| AST, POST DOSE DAY 3-10 | 9.0 ± NA | — | — |
| GGT, ON IV TREATMENT/DAY 2 | -1.5 ± 7.68 | -1.9 ± 8.10 | -1.4 ± 10.15 |
| GGT, ON IV TREATMENT/DAY 3 | 1.7 ± 18.66 | 3.8 ± 12.23 | 1.9 ± 5.16 |
| GGT, ON IV TREATMENT/DAY 4 | — | -4.0 ± NA | — |
| GGT, ON IV TREATMENT/DAY 5 | 3.3 ± 21.70 | -2.5 ± 5.21 | — |
| GGT, ON IV TREATMENT/DAY 7 | 25.5 ± 0.71 | -3.0 ± 12.73 | — |
| GGT, ORAL - FIRST DAY | 3.3 ± 20.16 | 4.5 ± 16.25 | -1.1 ± 10.95 |
| GGT, ORAL - DAY 7-10 | 3.6 ± 17.06 | 7.5 ± 19.89 | -2.2 ± 14.75 |
| GGT, POST THERAPY DAY 12-18 | 3.0 ± 15.60 | 5.3 ± 21.08 | -3.9 ± 16.80 |
| GGT, FOLLOW UP DAY 21-28 | 6.0 ± 13.56 | 64.0 ± 89.91 | 3.0 ± NA |
| GGT, POST DOSE DAY 3-10 | 39.0 ± NA | — | — |
Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Gram per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Albumin, ON IV TREATMENT/DAY 2 | -2.4 ± 3.57 | -1.1 ± 2.93 | -2.9 ± 3.34 |
| Albumin, ON IV TREATMENT/DAY 3 | -1.7 ± 4.09 | -0.6 ± 3.52 | -2.0 ± 3.46 |
| Albumin, ON IV TREATMENT/DAY 4 | — | 1.0 ± NA | — |
| Albumin, ON IV TREATMENT/DAY 5 | -1.1 ± 4.09 | -1.5 ± 3.62 | — |
| Albumin, ON IV TREATMENT/DAY 7 | 4.0 ± 8.49 | -0.5 ± 0.71 | — |
| Albumin, ORAL - FIRST DAY | 0.0 ± 3.39 | -0.2 ± 3.37 | -0.9 ± 2.86 |
| Albumin, ORAL - DAY 7-10 | 1.8 ± 3.58 | 1.4 ± 3.04 | 1.2 ± 2.51 |
| Albumin, POST THERAPY DAY 12-18 | 2.1 ± 3.81 | 2.8 ± 4.41 | 0.8 ± 3.61 |
| Albumin, FOLLOW UP DAY 21-28 | 2.8 ± 2.36 | 0.3 ± 2.22 | 0.0 ± NA |
| Albumin, POST DOSE DAY 3-10 | -4.0 ± NA | — | — |
| Protein, ON IV TREATMENT/DAY 2 | -3.2 ± 6.36 | -1.9 ± 5.86 | -5.2 ± 6.28 |
| Protein, ON IV TREATMENT/DAY 3 | -1.6 ± 7.04 | -0.3 ± 5.88 | -4.8 ± 6.59 |
| Protein, ON IV TREATMENT/DAY 4 | — | 0.0 ± NA | — |
| Protein, ON IV TREATMENT/DAY 5 | -0.5 ± 8.22 | -2.3 ± 7.34 | — |
| Protein, ON IV TREATMENT/DAY 7 | 5.5 ± 13.44 | -1.0 ± 8.49 | — |
| Protein, ORAL - FIRST DAY | 1.4 ± 5.96 | -0.2 ± 6.82 | -1.2 ± 5.05 |
| Protein, ORAL - DAY 7-10 | 3.1 ± 6.95 | 2.2 ± 5.88 | 0.5 ± 3.59 |
| Protein, POST THERAPY DAY 12-18 | 2.9 ± 7.21 | 3.1 ± 9.14 | -1.1 ± 5.93 |
| Protein, FOLLOW UP DAY 21-28 | 5.0 ± 5.29 | 0.8 ± 5.06 | -7.0 ± NA |
| Protein, POST DOSE DAY 3-10 | -3.0 ± NA | — | — |
Blood samples for assessment of clinical chemistry parameters of bilirubin, creatinine, direct bilirubin and urate was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Micromoles per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Bilirubin, ON IV TREATMENT/DAY 2 | -1.9 ± 3.22 | -1.3 ± 2.87 | -2.4 ± 3.34 |
| Bilirubin, ON IV TREATMENT/DAY 3 | -2.8 ± 4.42 | -1.0 ± 3.61 | -2.2 ± 2.73 |
| Bilirubin, ON IV TREATMENT/DAY 4 | — | -4.0 ± NA | — |
| Bilirubin, ON IV TREATMENT/DAY 5 | -2.8 ± 4.64 | -4.0 ± 2.53 | — |
| Bilirubin, ON IV TREATMENT/DAY 7 | 0.0 ± 0.0 | -4.0 ± 0.00 | — |
| Bilirubin, ORAL - FIRST DAY | -1.9 ± 3.87 | -1.7 ± 3.12 | -2.4 ± 2.69 |
| Bilirubin, ORAL - DAY 7-10 | -0.9 ± 4.17 | -0.7 ± 2.49 | -1.7 ± 2.55 |
| Bilirubin, POST THERAPY DAY 12-18 | -1.0 ± 4.35 | -0.5 ± 3.25 | -1.4 ± 3.83 |
| Bilirubin, FOLLOW UP DAY 21-28 | 0.0 ± 8.72 | 0.0 ± 4.69 | -1.3 ± 6.11 |
| Bilirubin, POST DOSE DAY 3-10 | -2.0 ± NA | — | — |
| Creatinine, ON IV TREATMENT/DAY 2 | 3.45 ± 11.885 | -2.33 ± 19.886 | 0.66 ± 8.711 |
| Creatinine, ON IV TREATMENT/DAY 3 | 1.30 ± 10.462 | -5.35 ± 28.787 | -3.93 ± 12.123 |
| Creatinine, ON IV TREATMENT/DAY 4 | — | -1.70 ± NA | — |
| Creatinine, ON IV TREATMENT/DAY 5 | -0.91 ± 10.541 | 7.37 ± 8.704 | — |
| Creatinine, ON IV TREATMENT/DAY 7 | 8.40 ± 10.607 | 6.65 ± 8.132 | — |
| Creatinine, ORAL - FIRST DAY | 4.22 ± 11.115 | -3.78 ± 27.598 | 2.37 ± 10.268 |
| Creatinine, ORAL - DAY 7-10 | 4.65 ± 9.930 | 0.72 ± 30.659 | 4.13 ± 9.518 |
| Creatinine, POST THERAPY DAY 12-18 | 3.82 ± 10.641 | 2.93 ± 26.419 | 2.08 ± 9.293 |
| Creatinine, FOLLOW UP DAY 21-28 | 9.92 ± 12.289 | -1.80 ± 2.846 | 2.70 ± NA |
| Creatinine, POST DOSE DAY 3-10 | -2.70 ± NA | — | — |
| Direct Bilirubin, ON IV TREATMENT/DAY 2 | -0.3 ± 2.09 | -0.6 ± 1.79 | -1.1 ± 2.28 |
| Direct Bilirubin, ON IV TREATMENT/DAY 3 | -0.2 ± 2.33 | -0.7 ± 1.83 | -1.3 ± 2.24 |
| Direct Bilirubin, ON IV TREATMENT/DAY 4 | — | -2.0 ± NA | — |
| Direct Bilirubin, ON IV TREATMENT/DAY 5 | -1.0 ± 1.94 | -0.7 ± 2.73 | — |
| Direct Bilirubin, ON IV TREATMENT/DAY 7 | -1.0 ± 1.41 | -3.0 ± 1.41 | — |
| Direct Bilirubin, ORAL - FIRST DAY | -0.4 ± 2.15 | -0.2 ± 2.19 | -1.0 ± 2.08 |
| Direct Bilirubin, ORAL - DAY 7-10 | 0.0 ± 1.95 | 0.0 ± 2.10 | -1.0 ± 2.16 |
| Direct Bilirubin, POST THERAPY DAY 12-18 | -0.3 ± 2.02 | 0.0 ± 1.68 | -1.2 ± 2.03 |
| Direct Bilirubin, FOLLOW UP DAY 21-28 | 1.5 ± 5.00 | 0.5 ± 1.91 | 0.0 ± NA |
| Direct Bilirubin, POST DOSE DAY 3-10 | 0.0 ± NA | — | — |
| Urate, ON IV TREATMENT/DAY 2 | 1.2 ± 44.16 | -11.7 ± 42.46 | -17.1 ± 50.43 |
| Urate, ON IV TREATMENT/DAY 3 | 4.2 ± 66.33 | 5.7 ± 52.02 | -14.4 ± 97.10 |
| Urate, ON IV TREATMENT/DAY 4 | — | 60.0 ± NA | — |
| Urate, ON IV TREATMENT/DAY 5 | 26.0 ± 89.47 | 46.7 ± 50.86 | — |
| Urate, ON IV TREATMENT/DAY 7 | 10.0 ± 169.71 | 90.0 ± 28.28 | — |
| Urate, ORAL - FIRST DAY | 16.3 ± 52.46 | 2.9 ± 67.26 | -1.3 ± 67.71 |
| Urate, ORAL - DAY 7-10 | 51.6 ± 55.31 | 67.0 ± 69.79 | 55.2 ± 65.32 |
| Urate, POST THERAPY DAY 12-18 | 60.8 ± 73.88 | 49.4 ± 83.24 | 45.3 ± 60.31 |
| Urate, FOLLOW UP DAY 21-28 | 7.5 ± 80.16 | 10.0 ± 102.31 | 140.0 ± NA |
| Urate, POST DOSE DAY 3-10 | 70.0 ± NA | — | — |
Blood samples for assessment of clinical chemistry parameters of calcium, carbon dioxide, chloride, glucose, magnesium, potassium, sodium and urea was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Millimole per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Calcium, ON IV TREATMENT/DAY 2 | -0.041 ± 0.1095 | -0.018 ± 0.1227 | -0.048 ± 0.1221 |
| Calcium, ON IV TREATMENT/DAY 3 | -0.007 ± 0.1732 | 0.019 ± 0.1247 | -0.009 ± 0.1289 |
| Calcium, ON IV TREATMENT/DAY 4 | — | -0.180 ± NA | — |
| Calcium, ON IV TREATMENT/DAY 5 | 0.024 ± 0.1313 | -0.007 ± 0.1440 | — |
| Calcium, ON IV TREATMENT/DAY 7 | 0.080 ± NA | 0.040 ± 0.2263 | — |
| Calcium, ORAL - FIRST DAY | 0.042 ± 0.1152 | 0.022 ± 0.1245 | 0.018 ± 0.0908 |
| Calcium, ORAL - DAY 7-10 | 0.093 ± 0.1373 | 0.064 ± 0.1063 | 0.030 ± 0.1231 |
| Calcium, POST THERAPY DAY 12-18 | 0.083 ± 0.1440 | 0.087 ± 0.1363 | 0.047 ± 0.1239 |
| Calcium, FOLLOW UP DAY 21-28 | 0.090 ± 0.1685 | 0.060 ± 0.0673 | 0.060 ± NA |
| Calcium, POST DOSE DAY 3-10 | -0.040 ± NA | — | — |
| Carbon Dioxide, ON IV TREATMENT/DAY 2 | -0.5 ± 2.87 | -0.3 ± 2.46 | 0.1 ± 2.49 |
| Carbon Dioxide, ON IV TREATMENT/DAY 3 | -0.5 ± 3.34 | -0.6 ± 2.71 | 0.4 ± 2.19 |
| Carbon Dioxide, ON IV TREATMENT/DAY 4 | — | 1.0 ± NA | — |
| Carbon Dioxide, ON IV TREATMENT/DAY 5 | 0.1 ± 4.28 | 0.7 ± 3.39 | — |
| Carbon Dioxide, ON IV TREATMENT/DAY 7 | 6.0 ± NA | 2.5 ± 2.12 | — |
| Carbon Dioxide, ORAL - FIRST DAY | -0.5 ± 3.14 | 0.1 ± 2.55 | -0.4 ± 2.97 |
| Carbon Dioxide, ORAL - DAY 7-10 | -0.5 ± 2.43 | 0.4 ± 2.87 | -0.2 ± 3.09 |
| Carbon Dioxide, POST THERAPY DAY 12-18 | -0.3 ± 2.83 | -0.1 ± 3.32 | 1.0 ± 1.73 |
| Carbon Dioxide, FOLLOW UP DAY 21-28 | -1.5 ± 3.32 | 2.3 ± 1.89 | 1.0 ± NA |
| Carbon Dioxide, POST DOSE DAY 3-10 | -4.0 ± NA | — | — |
| Chloride, ON IV TREATMENT/DAY 2 | 2.1 ± 2.32 | 1.3 ± 2.92 | 2.4 ± 2.98 |
| Chloride, ON IV TREATMENT/DAY 3 | 2.3 ± 2.92 | 1.4 ± 2.78 | 2.1 ± 4.04 |
| Chloride, ON IV TREATMENT/DAY 4 | — | -1.0 ± NA | — |
| Chloride, ON IV TREATMENT/DAY 5 | 2.9 ± 2.73 | 0.5 ± 1.05 | — |
| Chloride, ON IV TREATMENT/DAY 7 | -0.5 ± 0.71 | 0.5 ± 0.71 | — |
| Chloride, ORAL - FIRST DAY | 1.4 ± 2.52 | 0.4 ± 2.70 | 1.1 ± 3.13 |
| Chloride, ORAL - DAY 7-10 | 0.8 ± 3.63 | 0.7 ± 2.23 | 1.2 ± 2.93 |
| Chloride, POST THERAPY DAY 12-18 | 1.7 ± 2.75 | 1.6 ± 3.21 | 1.8 ± 2.95 |
| Chloride, FOLLOW UP DAY 21-28 | 0.5 ± 4.93 | -3.0 ± 2.94 | 3.0 ± NA |
| Chloride, POST DOSE DAY 3-10 | 4.0 ± NA | — | — |
| Glucose, ON IV TREATMENT/DAY 2 | 0.32 ± 1.973 | -0.31 ± 2.863 | -0.88 ± 2.462 |
| Glucose, ON IV TREATMENT/DAY 3 | 0.40 ± 2.144 | 0.48 ± 3.087 | -0.37 ± 2.384 |
| Glucose, ON IV TREATMENT/DAY 4 | — | 6.60 ± NA | — |
| Glucose, ON IV TREATMENT/DAY 5 | -0.51 ± 3.257 | 1.92 ± 1.723 | — |
| Glucose, ON IV TREATMENT/DAY 7 | -2.65 ± 4.313 | 3.70 ± 2.687 | — |
| Glucose, ORAL - FIRST DAY | 0.11 ± 2.115 | 0.13 ± 2.926 | -0.04 ± 1.619 |
| Glucose, ORAL - DAY 7-10 | 0.14 ± 1.698 | 1.08 ± 3.066 | -0.46 ± 1.741 |
| Glucose, POST THERAPY DAY 12-18 | -0.19 ± 1.774 | 0.34 ± 2.719 | -0.84 ± 2.068 |
| Glucose, FOLLOW UP DAY 21-28 | -0.38 ± 1.284 | 1.95 ± 3.450 | -0.10 ± NA |
| Glucose, POST DOSE DAY 3-10 | 0.30 ± NA | — | — |
| Magnesium, ON IV TREATMENT/DAY 2 | -0.013 ± 0.0682 | -0.017 ± 0.0688 | 0.004 ± 0.0865 |
| Magnesium, ON IV TREATMENT/DAY 3 | 0.007 ± 0.0829 | -0.012 ± 0.0553 | 0.018 ± 0.0689 |
| Magnesium, ON IV TREATMENT/DAY 4 | — | 0.000 ± NA | — |
| Magnesium, ON IV TREATMENT/DAY 5 | 0.044 ± 0.0532 | -0.040 ± 0.0738 | — |
| Magnesium, ON IV TREATMENT/DAY 7 | 0.140 ± 0.0000 | -0.080 ± 0.0283 | — |
| Magnesium, ORAL - FIRST DAY | -0.009 ± 0.0709 | -0.016 ± 0.0592 | 0.006 ± 0.0613 |
| Magnesium, ORAL - DAY 7-10 | 0.006 ± 0.0810 | -0.007 ± 0.0708 | 0.021 ± 0.0659 |
| Magnesium, POST THERAPY DAY 12-18 | -0.005 ± 0.0864 | 0.006 ± 0.0870 | -0.008 ± 0.0737 |
| Magnesium, FOLLOW UP DAY 21-28 | 0.000 ± 0.1347 | -0.040 ± 0.0283 | 0.000 ± NA |
| Magnesium, POST DOSE DAY 3-10 | -0.040 ± NA | — | — |
| Potassium, ON IV TREATMENT/DAY 2 | 0.15 ± 0.398 | 0.07 ± 0.481 | 0.22 ± 0.458 |
| Potassium, ON IV TREATMENT/DAY 3 | 0.24 ± 0.353 | 0.11 ± 0.429 | 0.16 ± 0.433 |
| Potassium, ON IV TREATMENT/DAY 4 | — | -0.10 ± NA | — |
| Potassium, ON IV TREATMENT/DAY 5 | 0.28 ± 0.559 | 0.02 ± 0.183 | — |
| Potassium, ON IV TREATMENT/DAY 7 | — | 0.55 ± 0.495 | — |
| Potassium, ORAL - FIRST DAY | 0.36 ± 0.374 | 0.20 ± 0.468 | 0.27 ± 0.365 |
| Potassium, ORAL - DAY 7-10 | 0.29 ± 0.483 | 0.06 ± 0.434 | 0.05 ± 0.533 |
| Potassium, POST THERAPY DAY 12-18 | 0.28 ± 0.543 | 0.06 ± 0.573 | 0.22 ± 0.487 |
| Potassium, FOLLOW UP DAY 21-28 | 1.03 ± 0.877 | -0.35 ± 0.998 | 0.60 ± NA |
| Potassium, POST DOSE DAY 3-10 | -0.10 ± NA | — | — |
| Sodium, ON IV TREATMENT/DAY 2 | 1.1 ± 2.34 | 0.9 ± 2.67 | 1.6 ± 1.93 |
| Sodium, ON IV TREATMENT/DAY 3 | 1.2 ± 2.59 | 1.0 ± 2.65 | 1.4 ± 4.16 |
| Sodium, ON IV TREATMENT/DAY 4 | — | -3.0 ± NA | — |
| Sodium, ON IV TREATMENT/DAY 5 | 2.8 ± 2.78 | 1.0 ± 2.90 | — |
| Sodium, ON IV TREATMENT/DAY 7 | 2.0 ± 2.83 | 0.0 ± 8.49 | — |
| Sodium, ORAL - FIRST DAY | 1.2 ± 2.55 | 0.3 ± 3.05 | 1.2 ± 2.54 |
| Sodium, ORAL - DAY 7-10 | 0.8 ± 2.44 | 0.5 ± 2.90 | 1.3 ± 2.55 |
| Sodium, POST THERAPY DAY 12-18 | 1.1 ± 2.53 | 1.4 ± 2.70 | 1.8 ± 2.93 |
| Sodium, FOLLOW UP DAY 21-28 | -3.0 ± 2.71 | -2.3 ± 2.87 | 1.0 ± NA |
| Sodium, POST DOSE DAY 3-10 | 5.0 ± NA | — | — |
| Urea, ON IV TREATMENT/DAY 2 | -0.11 ± 1.308 | -0.11 ± 1.189 | -0.58 ± 1.110 |
| Urea, ON IV TREATMENT/DAY 3 | -0.12 ± 1.484 | -0.24 ± 1.715 | -0.61 ± 2.088 |
| Urea, ON IV TREATMENT/DAY 4 | — | -1.00 ± NA | — |
| Urea, ON IV TREATMENT/DAY 5 | -0.50 ± 1.414 | 0.42 ± 1.320 | — |
| Urea, ON IV TREATMENT/DAY 7 | 1.00 ± 2.121 | -0.25 ± 1.061 | — |
| Urea, ORAL - FIRST DAY | -0.13 ± 1.360 | -0.56 ± 1.650 | -0.41 ± 1.379 |
| Urea, ORAL - DAY 7-10 | 0.77 ± 1.576 | 0.10 ± 1.945 | 0.29 ± 1.586 |
| Urea, POST THERAPY DAY 12-18 | 0.60 ± 1.563 | 0.63 ± 1.437 | -0.03 ± 1.486 |
| Urea, FOLLOW UP DAY 21-28 | 1.63 ± 2.016 | 0.25 ± 1.041 | -1.00 ± NA |
| Urea, POST DOSE DAY 3-10 | 0.00 ± NA | — | — |
Blood samples for assessment of clinical chemistry parameter of estimated creatinine clearance was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Milliliter per minute | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 2 | -6.8 ± 22.65 | -1.8 ± 17.47 | -1.7 ± 17.98 |
| ON IV TREATMENT/DAY 3 | -4.8 ± 32.17 | 1.7 ± 30.02 | 3.8 ± 19.70 |
| ON IV TREATMENT/DAY 4 | — | 5.0 ± NA | — |
| ON IV TREATMENT/DAY 5 | -17.4 ± 59.39 | -14.5 ± 14.92 | — |
| ON IV TREATMENT/DAY 7 | -22.0 ± 29.70 | -9.5 ± 13.44 | — |
| ORAL - FIRST DAY | -12.6 ± 32.53 | -1.1 ± 31.43 | -6.3 ± 16.45 |
| ORAL - DAY 7-10 | -13.2 ± 29.04 | -9.7 ± 36.67 | -8.3 ± 16.53 |
| POST THERAPY DAY 12-18 | -8.8 ± 28.55 | -10.4 ± 24.61 | -5.6 ± 12.72 |
| FOLLOW UP DAY 21-28 | -13.7 ± 25.54 | 3.8 ± 5.74 | — |
| POST DOSE DAY 3-10 | 6.0 ± NA | — | — |
Blood samples for assessment of clinical chemistry parameter of estradiol was collected at Baseline (Day 1). No post-baseline values were reported.
| Picomole per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Estradiol Values at Baseline | 229.4 ± 196.66 | 148.8 ± 153.58 | 23.5 ± 23.33 |
Blood samples for assessment of hematology parameters of basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Giga cells per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Basophils, ON IV TREATMENT/DAY 2 | 0.000 ± 0.0330 | 0.003 ± 0.0220 | 0.007 ± 0.0216 |
| Basophils, ON IV TREATMENT/DAY 3 | -0.003 ± 0.0262 | 0.003 ± 0.0217 | -0.014 ± 0.0305 |
| Basophils, ON IV TREATMENT/DAY 4 | — | -0.020 ± NA | — |
| Basophils, ON IV TREATMENT/DAY 5 | 0.008 ± 0.0212 | 0.007 ± 0.0437 | — |
| Basophils, ON IV TREATMENT/DAY 7 | 0.013 ± 0.0206 | 0.000 ± NA | — |
| Basophils, ON IV TREATMENT/DAY 10 | -0.020 ± NA | — | — |
| Basophils, ORAL - FIRST DAY | 0.000 ± 0.0310 | 0.000 ± 0.0185 | -0.004 ± 0.0171 |
| Basophils, ORAL - DAY 7-10 | 0.001 ± 0.0277 | 0.007 ± 0.0258 | 0.004 ± 0.0169 |
| Basophils, POST THERAPY DAY 12-18 | 0.005 ± 0.0304 | 0.001 ± 0.0217 | 0.001 ± 0.0190 |
| Basophils, FOLLOW UP DAY 21-28 | 0.016 ± 0.0114 | -0.020 ± NA | -0.007 ± 0.0404 |
| Basophils, POST DOSE DAY 3-10 | 0.040 ± NA | — | — |
| Eosinophils, ON IV TREATMENT/DAY 2 | 0.021 ± 0.1597 | 0.055 ± 0.1414 | 0.052 ± 0.0744 |
| Eosinophils, ON IV TREATMENT/DAY 3 | 0.010 ± 0.1405 | 0.024 ± 0.1474 | 0.016 ± 0.0995 |
| Eosinophils, ON IV TREATMENT/DAY 4 | — | 0.250 ± NA | — |
| Eosinophils, ON IV TREATMENT/DAY 5 | 0.026 ± 0.0826 | 0.025 ± 0.1245 | — |
| Eosinophils, ON IV TREATMENT/DAY 7 | 0.055 ± 0.1723 | 0.040 ± NA | — |
| Eosinophils, ON IV TREATMENT/DAY 10 | 0.010 ± NA | — | — |
| Eosinophils, ORAL - FIRST DAY | 0.013 ± 0.1443 | 0.051 ± 0.2001 | 0.027 ± 0.0927 |
| Eosinophils, ORAL - DAY 7-10 | 0.014 ± 0.1492 | 0.001 ± 0.1391 | 0.052 ± 0.1066 |
| Eosinophils, POST THERAPY DAY 12-18 | -0.017 ± 0.1168 | 0.011 ± 0.1320 | 0.050 ± 0.1298 |
| Eosinophils, FOLLOW UP DAY 21-28 | -0.004 ± 0.0716 | 0.000 ± NA | 0.060 ± 0.0436 |
| Eosinophils, POST DOSE DAY 3-10 | 0.360 ± NA | — | — |
| Leukocytes, ON IV TREATMENT/DAY 2 | -1.39 ± 2.722 | -1.35 ± 2.251 | -1.47 ± 2.086 |
| Leukocytes, ON IV TREATMENT/DAY 3 | -2.04 ± 3.091 | -1.80 ± 2.692 | -2.94 ± 4.222 |
| Leukocytes, ON IV TREATMENT/DAY 4 | — | -7.10 ± NA | — |
| Leukocytes, ON IV TREATMENT/DAY 5 | -2.49 ± 4.376 | -2.57 ± 1.402 | — |
| Leukocytes, ON IV TREATMENT/DAY 7 | -4.55 ± 5.108 | -2.90 ± NA | — |
| Leukocytes, ON IV TREATMENT/DAY 10 | -11.20 ± NA | — | — |
| Leukocytes, ORAL - FIRST DAY | -1.31 ± 2.959 | -2.32 ± 2.527 | -1.69 ± 2.641 |
| Leukocytes, ORAL - DAY 7-10 | -1.08 ± 2.482 | -1.91 ± 2.299 | -1.67 ± 2.637 |
| Leukocytes, POST THERAPY DAY 12-18 | -2.15 ± 3.053 | -2.20 ± 2.464 | -2.25 ± 3.152 |
| Leukocytes, FOLLOW UP DAY 21-28 | -2.06 ± 2.428 | -5.70 ± NA | -3.23 ± 5.877 |
| Leukocytes, POST DOSE DAY 3-10 | -12.60 ± NA | — | — |
| Lymphocytes, ON IV TREATMENT/DAY 2 | 0.019 ± 0.6137 | 0.009 ± 0.5047 | 0.358 ± 0.7229 |
| Lymphocytes, ON IV TREATMENT/DAY 3 | 0.263 ± 0.5574 | 0.094 ± 0.3504 | 0.129 ± 0.5742 |
| Lymphocytes, ON IV TREATMENT/DAY 4 | — | 0.790 ± NA | — |
| Lymphocytes, ON IV TREATMENT/DAY 5 | 0.288 ± 0.6918 | 0.075 ± 0.5417 | — |
| Lymphocytes, ON IV TREATMENT/DAY 7 | 0.705 ± 0.5291 | 0.200 ± NA | — |
| Lymphocytes, ON IV TREATMENT/DAY 10 | 1.230 ± NA | — | — |
| Lymphocytes, ORAL - FIRST DAY | 0.002 ± 0.6844 | -0.050 ± 0.7343 | 0.247 ± 0.8342 |
| Lymphocytes, ORAL - DAY 7-10 | 0.222 ± 0.6592 | 0.204 ± 0.7131 | 0.284 ± 0.6655 |
| Lymphocytes, POST-THERAPY DAY 12-18 | 0.179 ± 0.7122 | 0.028 ± 0.6588 | 0.184 ± 0.5295 |
| Lymphocytes, FOLLOW UP DAY 21-28 | 0.326 ± 0.3564 | -0.020 ± NA | 0.097 ± 0.2743 |
| Lymphocytes, POST DOSE DAY 3-10 | 0.850 ± NA | — | — |
| Monocytes, ON IV TREATMENT/DAY 2 | -0.054 ± 0.1938 | -0.030 ± 0.2160 | -0.011 ± 0.2524 |
| Monocytes, ON IV TREATMENT/DAY 3 | -0.002 ± 0.2326 | -0.133 ± 0.2330 | -0.219 ± 0.5008 |
| Monocytes, ON IV TREATMENT/DAY 4 | — | -0.280 ± NA | — |
| Monocytes, ON IV TREATMENT/DAY 5 | -0.114 ± 0.2056 | -0.243 ± 0.2448 | — |
| Monocytes, ON IV TREATMENT/DAY 7 | 0.022 ± 0.3231 | -0.170 ± NA | — |
| Monocytes, ON IV TREATMENT/DAY 10 | -0.240 ± NA | — | — |
| Monocytes, ORAL - FIRST DAY | -0.076 ± 0.2069 | -0.099 ± 0.2379 | -0.154 ± 0.2919 |
| Monocytes, ORAL - DAY 7-10 | -0.014 ± 0.2030 | -0.067 ± 0.1690 | -0.070 ± 0.3348 |
| Monocytes, POST THERAPY DAY 12-18 | -0.077 ± 0.1442 | -0.130 ± 0.2240 | -0.133 ± 0.3065 |
| Monocytes, FOLLOW UP DAY 21-28 | 0.018 ± 0.2969 | 0.050 ± NA | -0.347 ± 0.7050 |
| Monocytes, POST DOSE DAY 3-10 | 0.280 ± NA | — | — |
| Neutrophils, ON IV TREATMENT/DAY 2 | -1.373 ± 2.7464 | -1.395 ± 2.4280 | -1.873 ± 2.0729 |
| Neutrophils, ON IV TREATMENT/DAY 3 | -2.324 ± 3.2252 | -1.789 ± 2.6403 | -2.854 ± 3.6332 |
| Neutrophils, ON IV TREATMENT/DAY 4 | — | -7.880 ± NA | — |
| Neutrophils, ON IV TREATMENT/DAY 5 | -2.712 ± 4.5024 | -2.445 ± 0.9370 | — |
| Neutrophils, ON IV TREATMENT/DAY 7 | -5.403 ± 5.1790 | -2.910 ± NA | — |
| Neutrophils, ON IV TREATMENT/DAY 10 | -12.250 ± NA | — | — |
| Neutrophils, ORAL - FIRST DAY | -1.244 ± 3.0855 | -2.229 ± 2.6921 | -1.802 ± 2.5066 |
| Neutrophils, ORAL - DAY 7-10 | -1.363 ± 2.4532 | -2.068 ± 2.3963 | -1.930 ± 2.7752 |
| Neutrophils, POST THERAPY DAY 12-18 | -2.243 ± 3.2754 | -2.111 ± 2.6465 | -2.346 ± 3.0470 |
| Neutrophils, FOLLOW UP DAY 21-28 | -2.436 ± 2.5072 | -5.770 ± NA | -3.007 ± 5.4347 |
| Neutrophils, POST DOSE DAY 3-10 | -14.050 ± NA | — | — |
| Platelets, ON IV TREATMENT/DAY 2 | 5.6 ± 37.64 | 6.3 ± 41.11 | -6.7 ± 57.38 |
| Platelets, ON IV TREATMENT/DAY 3 | 5.8 ± 44.94 | 3.1 ± 41.89 | -0.6 ± 19.64 |
| Platelets, ON IV TREATMENT/DAY 4 | — | -30.0 ± NA | — |
| Platelets, ON IV TREATMENT/DAY 5 | 43.7 ± 78.78 | 21.3 ± 33.02 | — |
| Platelets, ON IV TREATMENT/DAY 7 | 77.8 ± 107.48 | -9.0 ± NA | — |
| Platelets, ON IV TREATMENT/DAY 10 | 159.0 ± NA | — | — |
| Platelets, ORAL - FIRST DAY | 44.0 ± 74.12 | 0.1 ± 73.36 | 11.6 ± 52.46 |
| Platelets, ORAL - DAY 7-10 | 22.7 ± 55.11 | 33.9 ± 95.63 | 22.0 ± 63.18 |
| Platelets, POST THERAPY DAY 12-18 | 17.5 ± 76.72 | 2.9 ± 88.15 | 0.6 ± 56.26 |
| Platelets, FOLLOW UP DAY 21-28 | 21.0 ± 26.44 | -92.0 ± NA | -23.3 ± 62.93 |
| Platelets, POST DOSE DAY 3-10 | 148.0 ± NA | — | — |
Blood samples for assessment of hematology parameters of EMCHC and hemoglobin was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Gram per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| EMCHC, ON IV TREATMENT/DAY 2 | 1.2 ± 6.08 | 2.0 ± 6.90 | 0.1 ± 6.94 |
| EMCHC, ON IV TREATMENT/DAY 3 | -0.4 ± 6.64 | 2.9 ± 7.67 | 2.9 ± 7.90 |
| EMCHC, ON IV TREATMENT/DAY 4 | — | 0.0 ± NA | — |
| EMCHC, ON IV TREATMENT/DAY 5 | -4.3 ± 7.51 | 5.8 ± 10.85 | — |
| EMCHC, ON IV TREATMENT/DAY 7 | 2.8 ± 9.60 | 6.0 ± NA | — |
| EMCHC, ON IV TREATMENT/DAY 10 | -6.0 ± NA | — | — |
| EMCHC, ORAL - FIRST DAY | 1.2 ± 8.08 | 0.9 ± 8.23 | 1.1 ± 6.13 |
| EMCHC, ORAL - DAY 7-10 | 2.8 ± 5.55 | 2.1 ± 7.06 | 2.1 ± 8.46 |
| EMCHC, POST THERAPY DAY 12-18 | 1.6 ± 6.49 | 2.1 ± 6.83 | 0.6 ± 7.93 |
| EMCHC, FOLLOW UP DAY 21-28 | 5.6 ± 10.81 | 0.0 ± NA | 8.3 ± 13.32 |
| EMCHC, POST DOSE DAY 3-10 | 21.0 ± NA | — | — |
| Hemoglobin, ON IV TREATMENT/DAY 2 | -3.0 ± 9.04 | -1.2 ± 9.10 | -4.0 ± 8.79 |
| Hemoglobin, ON IV TREATMENT/DAY 3 | -2.2 ± 10.95 | -2.2 ± 11.13 | -1.6 ± 8.22 |
| Hemoglobin, ON IV TREATMENT/DAY 4 | — | -8.0 ± NA | — |
| Hemoglobin, ON IV TREATMENT/DAY 5 | -4.7 ± 10.27 | -8.0 ± 13.93 | — |
| Hemoglobin, ON IV TREATMENT/DAY 7 | -9.8 ± 7.80 | 3.0 ± NA | — |
| Hemoglobin, ON IV TREATMENT/DAY 10 | -24.0 ± NA | — | — |
| Hemoglobin, ORAL - FIRST DAY | 4.2 ± 9.42 | -0.9 ± 12.20 | -1.0 ± 8.20 |
| Hemoglobin, ORAL - DAY 7-10 | 3.9 ± 11.18 | 1.8 ± 9.74 | -0.6 ± 7.45 |
| Hemoglobin, POST THERAPY DAY 12-18 | 3.8 ± 10.18 | 2.2 ± 9.02 | -0.1 ± 10.85 |
| Hemoglobin, FOLLOW UP DAY 21-28 | 8.4 ± 5.50 | -7.0 ± NA | 3.0 ± 15.87 |
| Hemoglobin, POST DOSE DAY 3-10 | -1.0 ± NA | — | — |
Blood samples for assessment of hematology parameter of EMCH was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Picograms | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 2 | 0.11 ± 0.413 | 0.04 ± 0.386 | -0.07 ± 0.354 |
| ON IV TREATMENT/DAY 3 | 0.00 ± 0.278 | 0.05 ± 0.495 | -0.03 ± 0.374 |
| ON IV TREATMENT/DAY 4 | — | -0.40 ± NA | — |
| ON IV TREATMENT/DAY 5 | -0.19 ± 0.325 | 0.12 ± 0.319 | — |
| ON IV TREATMENT/DAY 7 | 0.30 ± 0.294 | 0.20 ± NA | — |
| ON IV TREATMENT/DAY 10 | -0.20 ± NA | — | — |
| ORAL - FIRST DAY | 0.08 ± 0.408 | -0.01 ± 0.389 | -0.14 ± 0.333 |
| ORAL - DAY 7-10 | 0.01 ± 0.290 | -0.03 ± 0.390 | -0.06 ± 0.438 |
| POST THERAPY DAY 12-18 | -0.04 ± 0.389 | 0.01 ± 0.366 | -0.08 ± 0.709 |
| FOLLOW UP DAY 21-28 | 0.06 ± 0.483 | -0.40 ± NA | 1.20 ± 1.735 |
| POST DOSE DAY 3-10 | 0.10 ± NA | — | — |
Blood samples for assessment of hematology parameter of EMCV was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Femtoliter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 2 | 0.0 ± 1.73 | -0.4 ± 1.56 | -0.1 ± 1.90 |
| ON IV TREATMENT/DAY 3 | 0.0 ± 1.61 | -0.6 ± 1.63 | -0.9 ± 1.96 |
| ON IV TREATMENT/DAY 4 | — | -2.0 ± NA | — |
| ON IV TREATMENT/DAY 5 | 0.7 ± 2.06 | -1.0 ± 2.68 | — |
| ON IV TREATMENT/DAY 7 | 0.0 ± 3.65 | -1.0 ± NA | — |
| ON IV TREATMENT/DAY 10 | 1.0 ± NA | — | — |
| ORAL - FIRST DAY | 0.0 ± 1.96 | -0.3 ± 2.11 | -0.7 ± 1.66 |
| ORAL - DAY 7-10 | -0.8 ± 1.52 | -0.6 ± 1.50 | -0.9 ± 1.77 |
| POST THERAPY DAY 12-18 | -0.6 ± 1.76 | -0.5 ± 1.59 | -0.5 ± 1.68 |
| FOLLOW UP DAY 21-28 | -1.6 ± 1.82 | -2.0 ± NA | 2.3 ± 3.21 |
| POST DOSE DAY 3-10 | -7.0 ± NA | — | — |
Blood samples for assessment of hematology parameter of erythrocyte was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Trillion cells per liter | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 2 | -0.14 ± 0.332 | -0.04 ± 0.340 | -0.12 ± 0.345 |
| ON IV TREATMENT/DAY 3 | -0.09 ± 0.430 | -0.06 ± 0.430 | -0.07 ± 0.320 |
| ON IV TREATMENT/DAY 4 | — | -0.30 ± NA | — |
| ON IV TREATMENT/DAY 5 | -0.14 ± 0.373 | -0.28 ± 0.475 | — |
| ON IV TREATMENT/DAY 7 | -0.35 ± 0.238 | 0.10 ± NA | — |
| ON IV TREATMENT/DAY 10 | -0.80 ± NA | — | — |
| ORAL - FIRST DAY | 0.12 ± 0.362 | -0.01 ± 0.420 | -0.01 ± 0.317 |
| ORAL - DAY 7-10 | 0.12 ± 0.400 | 0.07 ± 0.383 | -0.01 ± 0.284 |
| POST THERAPY DAY 12-18 | 0.13 ± 0.360 | 0.07 ± 0.346 | 0.02 ± 0.416 |
| FOLLOW UP DAY 21-28 | 0.26 ± 0.182 | -0.20 ± NA | -0.03 ± 0.351 |
| POST DOSE DAY 3-10 | 0.00 ± NA | — | — |
Blood samples for assessment of hematology parameter of hematocrit was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.
| Ratio | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| ON IV TREATMENT/DAY 2 | -0.0111 ± 0.03004 | -0.0065 ± 0.03316 | -0.0125 ± 0.03152 |
| ON IV TREATMENT/DAY 3 | -0.0066 ± 0.03683 | -0.0099 ± 0.03922 | -0.0073 ± 0.02536 |
| ON IV TREATMENT/DAY 4 | — | -0.0260 ± NA | — |
| ON IV TREATMENT/DAY 5 | -0.0101 ± 0.03166 | -0.0322 ± 0.04462 | — |
| ON IV TREATMENT/DAY 7 | -0.0353 ± 0.01873 | 0.0020 ± NA | — |
| ON IV TREATMENT/DAY 10 | -0.0690 ± NA | — | — |
| ORAL - FIRST DAY | 0.0112 ± 0.03422 | -0.0041 ± 0.04091 | -0.0043 ± 0.02854 |
| ORAL - DAY 7-10 | 0.0080 ± 0.03674 | 0.0027 ± 0.03459 | -0.0040 ± 0.02840 |
| POST THERAPY DAY 12-18 | 0.0100 ± 0.03340 | 0.0039 ± 0.02846 | -0.0006 ± 0.04085 |
| FOLLOW UP DAY 21-28 | 0.0178 ± 0.01699 | -0.0220 ± NA | 0.0033 ± 0.03988 |
| POST DOSE DAY 3-10 | -0.0320 ± NA | — | — |
Samples for urinalysis assessment was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for Glucose, Ketones, Occult Blood, Protein and pH. Participants with abnormal urinalysis result was reported.
| Participants | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Glucose, BASELINE/DAY 1, Trace | 1 | 2 | 1 |
| Glucose, BASELINE/DAY 1, 1+ | 1 | 1 | 1 |
| Glucose, BASELINE/DAY 1, 3+ | 1 | 2 | 1 |
| Glucose, ON IV TREATMENT/DAY 2, Trace | 1 | 0 | 0 |
| Glucose, ON IV TREATMENT/DAY 2, 1+ | 0 | 0 | 2 |
| Glucose, ON IV TREATMENT/DAY 2, 3+ | 3 | 2 | 1 |
| Glucose, ON IV TREATMENT/DAY 3, 2+ | 1 | 1 | 0 |
| Glucose, ON IV TREATMENT/DAY 3, 3+ | 1 | 1 | 0 |
| Glucose, ON IV TREATMENT/DAY 5, 2+ | 1 | 0 | — |
| Glucose, ON IV TREATMENT/DAY 7, 2+ | 1 | 0 | — |
| Glucose, ORAL - FIRST DAY, Trace | 0 | 1 | 0 |
| Glucose, ORAL - FIRST DAY, 1+ | 1 | 0 | 0 |
| Glucose, ORAL - FIRST DAY, 3+ | 1 | 2 | 0 |
| Glucose, ORAL - DAY 7-10, Trace | 1 | 0 | 0 |
| Glucose, ORAL - DAY 7-10, 1+ | 0 | 1 | 0 |
| Glucose, ORAL - DAY 7-10, 2+ | 0 | 1 | 0 |
| Glucose, ORAL - DAY 7-10, 3+ | 0 | 2 | 0 |
| Glucose, POST THERAPY DAY 12-18, Trace | 3 | 0 | 0 |
| Glucose, POST THERAPY DAY 12-18, 1+ | 0 | 1 | 0 |
| Glucose, POST THERAPY DAY 12-18, 3+ | 0 | 3 | 0 |
| Ketones, BASELINE/DAY 1, Trace | 8 | 3 | 6 |
| Ketones, BASELINE/DAY 1, 1+ | 1 | 1 | 0 |
| Ketones, BASELINE/DAY 1, 3+ | 0 | 2 | 0 |
| Ketones, ON IV TREATMENT/DAY 2, Trace | 4 | 3 | 1 |
| Ketones, ON IV TREATMENT/DAY 2, 1+ | 2 | 1 | 0 |
| Ketones, ON IV TREATMENT/DAY 2, 3+ | 0 | 0 | 1 |
| Ketones, ON IV TREATMENT/DAY 3, Trace | 5 | 0 | 2 |
| Ketones, ORAL - FIRST DAY, Trace | 3 | 1 | 2 |
| Ketones, ORAL - FIRST DAY, 2+ | 1 | 0 | 0 |
| Ketones, ORAL - DAY 7-10, Trace | 6 | 3 | 3 |
| Ketones, POST THERAPY DAY 12-18, Trace | 8 | 6 | 2 |
| Occult Blood, BASELINE/DAY 1, Trace | 3 | 1 | 1 |
| Occult Blood, BASELINE/DAY 1, 1+ | 4 | 0 | 1 |
| Occult Blood, BASELINE/DAY 1, 2+ | 1 | 1 | 0 |
| Occult Blood, BASELINE/DAY 1, 3+ | 4 | 0 | 1 |
| Occult Blood, ON IV TREATMENT/DAY 2, Trace | 3 | 0 | 1 |
| Occult Blood, ON IV TREATMENT/DAY 2, 1+ | 1 | 0 | 0 |
| Occult Blood, ON IV TREATMENT/DAY 2, 2+ | 0 | 0 | 2 |
| Occult Blood, ON IV TREATMENT/DAY 2, 3+ | 1 | 1 | 0 |
| Occult Blood, ON IV TREATMENT/DAY 3, Trace | 0 | 1 | 0 |
| Occult Blood, ON IV TREATMENT/DAY 3, 3+ | 0 | 0 | 1 |
| Occult Blood, ON IV TREATMENT/DAY 5, Trace | 2 | 0 | — |
| Occult Blood, ON IV TREATMENT/DAY 7, Trace | 1 | 0 | — |
| Occult Blood, ORAL - FIRST DAY, Trace | 2 | 1 | 1 |
| Occult Blood, ORAL - FIRST DAY, 1+ | 3 | 1 | 0 |
| Occult Blood, ORAL - FIRST DAY, 2+ | 1 | 0 | 0 |
| Occult Blood, ORAL - FIRST DAY, 3+ | 0 | 1 | 0 |
| Occult Blood, ORAL - DAY 7-10, Trace | 1 | 0 | 1 |
| Occult Blood, ORAL - DAY 7-10, 2+ | 1 | 0 | 1 |
| Occult Blood, ORAL - DAY 7-10, 3+ | 0 | 0 | 1 |
| Occult Blood, POST THERAPY DAY 12-18, Trace | 1 | 1 | 1 |
| Occult Blood, POST THERAPY DAY 12-18, 1+ | 1 | 1 | 0 |
| Occult Blood, POST THERAPY DAY 12-18, 2+ | 1 | 1 | 0 |
| Occult Blood, POST THERAPY DAY 12-18, 3+ | 1 | 0 | 1 |
| Protein, BASELINE/DAY 1, Trace | 7 | 5 | 5 |
| Protein, BASELINE/DAY 1, 1+ | 6 | 4 | 5 |
| Protein, BASELINE/DAY 1, 2+ | 1 | 0 | 1 |
| Protein, BASELINE/DAY 1, 3+ | 1 | 0 | 0 |
| Protein, ON IV TREATMENT/DAY 2, Trace | 4 | 6 | 4 |
| Protein, ON IV TREATMENT/DAY 2, 1+ | 7 | 7 | 4 |
| Protein, ON IV TREATMENT/DAY 3, Trace | 4 | 3 | 0 |
| Protein, ON IV TREATMENT/DAY 3, 1+ | 3 | 2 | 3 |
| Protein, ON IV TREATMENT/DAY 3, 2+ | 1 | 0 | 0 |
| Protein, ON IV TREATMENT/DAY 5, Trace | 2 | 0 | — |
| Protein, ON IV TREATMENT/DAY 5, 1+ | 0 | 1 | — |
| Protein, ORAL - FIRST DAY, Trace | 2 | 3 | 1 |
| Protein, ORAL - FIRST DAY, 1+ | 0 | 4 | 2 |
| Protein, ORAL - FIRST DAY, 2+ | 1 | 0 | 0 |
| Protein, ORAL - DAY 7-10, Trace | 7 | 4 | 6 |
| Protein, ORAL - DAY 7-10, 1+ | 6 | 5 | 4 |
| Protein, ORAL - DAY 7-10, 2+ | 1 | 1 | 1 |
| Protein, POST THERAPY DAY 12-18, Trace | 8 | 6 | 2 |
| Protein, POST THERAPY DAY 12-18, 1+ | 3 | 4 | 3 |
| Protein, POST THERAPY DAY 12-18, 2+ | 0 | 1 | 0 |
| pH, Post-Baseline Maximum, 8.5 | 1 | 0 | 0 |
Collected over AEs were collected up to follow-up (Day 28).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gepotidacin 750 mg q12h | 0/58 (0%) | 1/58 (1.7%) | 30/58 (51.7%) |
| Gepotidacin 1000 mg q12h | 1/39 (2.6%) | 1/39 (2.6%) | 20/39 (51.3%) |
| Gepotidacin 1000 mg q8h | 0/25 (0%) | 0/25 (0%) | 14/25 (56%) |
| Event | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| Septic shockInfections and infestations | 0/58 | 1/39 | 0/25 |
| CellulitisInfections and infestations | 1/58 | 0/39 | 0/25 |
| Event | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h |
|---|---|---|---|
| NauseaGastrointestinal disorders | 12/58 | 9/39 | 4/25 |
| DiarrhoeaGastrointestinal disorders | 5/58 | 6/39 | 5/25 |
| VomitingGastrointestinal disorders | 3/58 | 2/39 | 3/25 |
| HeadacheNervous system disorders | 6/58 | 1/39 | 0/25 |
| FlatulenceGastrointestinal disorders | 3/58 | 1/39 | 2/25 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/58 | 0/39 | 2/25 |
| Alanine aminotransferase increasedInvestigations | 4/58 | 3/39 | 2/25 |
| Aspartate aminotransferase increasedInvestigations | 3/58 | 3/39 | 1/25 |
| Gamma-glutamyltransferase increasedInvestigations | 3/58 | 3/39 | 0/25 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 1/58 | 3/39 | 0/25 |
mITT population: those participants who received study treatment
| Age, Continuous(Years) | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h | Total |
|---|---|---|---|---|
| Mean | 44.3 ± 11.35 | 44.6 ± 10.76 | 45.8 ± 12.64 | 44.7 ± 11.36 |
| Sex: Female, Male(Participants) | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h | Total |
|---|---|---|---|---|
| Female | 18 | 12 | 5 | 35 |
| Male | 40 | 27 | 20 | 87 |
| Race (NIH/OMB)(Participants) | Gepotidacin 750 mg q12h | Gepotidacin 1000 mg q12h | Gepotidacin 1000 mg q8h | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 1 | 2 | 0 | 3 |
| White | 55 | 36 | 24 | 115 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Mar 2014 to primary completion in Jun 2015, 15 months.
Results were first posted in Sep 2017, 2 years 2 months after primary completion. A results delay was requested in Oct 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin